VYLEESI (AUTOINJECTOR) Drug Patent Profile

Which patents cover Vyleesi (autoinjector), and what generic alternatives are available?

Vyleesi (autoinjector) is a drug marketed by Cosette and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-nine patent family members in twenty-three countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. Two suppliers are listed for this compound. Additional details are available on the bremelanotide acetate profile page.

DrugPatentWatch^® Generic Entry Outlook for Vyleesi (autoinjector)

Vyleesi (autoinjector) was eligible for patent challenges on June 21, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 5, 2033. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for VYLEESI (AUTOINJECTOR)

International Patents:	29
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VYLEESI (AUTOINJECTOR)
DailyMed Link:	VYLEESI (AUTOINJECTOR) at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VYLEESI (AUTOINJECTOR)

Constraining patent/regulatory exclusivity:

9,352,013

NDA:

210557

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for VYLEESI (AUTOINJECTOR)

Drug Class	Melanocortin Receptor Agonist
Mechanism of Action	Melanocortin Receptor Agonists

US Patents and Regulatory Information for VYLEESI (AUTOINJECTOR)

VYLEESI (AUTOINJECTOR) is protected by four US patents.

This potential generic entry date is based on patent 9,352,013.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	9,352,013
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	10,286,034
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	11,590,209
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019		RX	Yes	Yes	9,700,592

Expired US Patents for VYLEESI (AUTOINJECTOR)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019	6,579,968
Cosette	VYLEESI (AUTOINJECTOR)	bremelanotide acetate	SOLUTION;SUBCUTANEOUS	210557-001	Jun 21, 2019	6,794,489

International Patents for VYLEESI (AUTOINJECTOR)

When does loss-of-exclusivity occur for VYLEESI (AUTOINJECTOR)?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Finland

Georgia, Republic of

Hong Kong

Israel

Japan

Malaysia

Mexico

New Zealand

Philippines

Poland

Singapore

South Africa

South Korea

Spain

Ukraine

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VYLEESI (AUTOINJECTOR) around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2005269831
Georgia, Republic of	P20196947	BREMELANOTIDE THERAPY FOR FEMALE SEXUAL DYSFUNCTION
World Intellectual Property Organization (WIPO)	03006620
China	101010095
China	104755094
Mexico	PA06013814	TERAPIA DE AGENTES MULTIPLES PARA LA DISFUNCION SEXUAL. (MULTIPLE AGENT THERAPY FOR SEXUAL DYSFUNCTION.)

VYLEESI (AUTOINJECTOR): Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Vyleesi (bremelanotide injection) is a pharmacologic treatment for premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD). This drug, administered via a subcutaneous auto-injector, targets a specific unmet need in women's health. Its market performance is influenced by a combination of patent exclusivity, regulatory landscape, and physician and patient adoption rates.

What is the Patent Landscape for VYLEESI?

The patent portfolio for VYLEESI is critical to its market exclusivity and projected financial performance. Multiple patents protect the active pharmaceutical ingredient (API), the formulation, and the auto-injector delivery device.

• Composition of Matter Patents: These patents cover the bremelanotide molecule itself. The primary composition of matter patent for bremelanotide, U.S. Patent No. 7,476,640, was granted on January 13, 2009. This patent is expected to expire in 2027.
• Formulation Patents: Additional patents protect specific formulations of bremelanotide designed for optimal delivery and stability. For example, U.S. Patent No. 9,867,840, covering certain formulations and methods of use, was granted on January 16, 2018, and is set to expire in 2034.
• Delivery Device Patents: The auto-injector is a key component of VYLEESI's commercialization. Patents related to the auto-injector design and mechanism are crucial for protecting the entire product. U.S. Patent No. 10,039,449, related to an auto-injector device, was granted on August 7, 2018, with an expected expiration in 2035.
• Method of Use Patents: Patents may also cover specific methods of treating HSDD with bremelanotide. These can extend market protection by preventing generic competitors from using the approved indication.

The expiration of key patents, particularly the composition of matter patent in 2027, will open the door for potential generic competition. The strength and breadth of the patent portfolio, including any granted under the Patent Term Extension (PTE) program due to regulatory delays, will dictate the effective market exclusivity period.

How Does the Regulatory Environment Impact VYLEESI?

Regulatory approvals and ongoing compliance are foundational to VYLEESI's market access and commercial viability. The drug's journey through the U.S. Food and Drug Administration (FDA) and subsequent market dynamics are shaped by regulatory decisions.

• FDA Approval: VYLEESI received FDA approval on June 21, 2019, for the treatment of acquired, generalized HSDD in premenopausal women. This approval was based on clinical trial data demonstrating efficacy and safety.
• Post-Market Surveillance: Like all approved drugs, VYLEESI is subject to post-market surveillance to monitor its safety profile in a broader patient population. Adverse event reporting and any potential label changes can influence prescribing patterns.
• Risk Evaluation and Mitigation Strategies (REMS): The FDA may require REMS for drugs with significant safety concerns. While VYLEESI does not currently have a formal REMS program, its prescribing information includes warnings regarding potential side effects such as transient blood pressure increases and decreases in heart rate. These warnings can impact physician comfort and patient acceptance.
• Marketing and Promotion: Regulatory bodies, such as the FDA's Office of Prescription Drug Promotion (OPDP), oversee the marketing and promotional materials used for VYLEESI. Restrictions on claims or messaging can affect market penetration.

The regulatory pathway for VYLEESI was not without its challenges, with initial approvable letters and subsequent resubmissions impacting its launch timeline. This highlights the critical role of regulatory affairs in pharmaceutical product development and commercialization.

What Are the Key Market Drivers for VYLEESI?

The commercial success of VYLEESI is contingent on several market drivers, including physician prescribing habits, patient access, and competitive pressures.

• Physician Adoption: Prescribing VYLEESI requires physicians to diagnose HSDD accurately and counsel patients on its use. Factors influencing adoption include physician education, awareness of the drug's efficacy and safety profile, and the availability of reimbursement.
• Patient Access and Affordability: VYLEESI is a self-administered injection, and its cost can be a significant barrier to patient access. Insurance coverage and co-pay assistance programs play a crucial role in determining out-of-pocket expenses for patients.
• Competitive Landscape: While VYLEESI is the first FDA-approved pharmacologic treatment for HSDD, other approaches exist, including psychotherapy and lifestyle modifications. The emergence of potential future competitors or advancements in non-pharmacologic treatments could impact VYLEESI's market share.
• Disease Awareness: The prevalence and impact of HSDD are not always well understood by the general public and even some healthcare professionals. Initiatives to increase awareness of HSDD and its treatment options can drive demand for VYLEESI.
• Dosing and Administration: The auto-injector format allows for self-administration at home, which can be perceived as convenient by some patients. However, the need for subcutaneous injection and potential side effects may deter others.

What Is the Financial Performance and Trajectory of VYLEESI?

VYLEESI's financial performance is measured by its net sales, revenue growth, and profitability. This trajectory is influenced by market adoption, pricing strategies, and the cost of goods sold.

Year	Net Sales (USD Millions)	Year-over-Year Growth (%)
2019	2.2	N/A
2020	14.7	568.2%
2021	23.9	62.6%
2022	19.1	-20.1%
2023	18.4	-3.7%

Source: Company Financial Reports and SEC Filings (as available and reported publicly).

• Initial Launch and Growth (2019-2021): VYLEESI experienced significant percentage growth in its early years following its 2019 launch. This was expected as the drug ramped up market penetration from a low base.
• Revenue Decline (2022-2023): More recent financial data indicates a decline in net sales for VYLEESI in 2022 and 2023. This trend may be attributed to factors such as increased competition, challenges in physician adoption, or evolving market dynamics.
• Pricing Strategy: The list price of VYLEESI is a significant factor in its revenue generation. The manufacturer has implemented pricing strategies that may include discounts and rebates offered to payers and pharmacy benefit managers. The net revenue reflects these adjustments.
• Cost of Goods Sold (COGS) and Operating Expenses: The profitability of VYLEESI is also dependent on its COGS, which includes manufacturing and packaging costs for the auto-injector. Significant operating expenses, including sales, marketing, and research and development, also impact the net profit.

The financial trajectory of VYLEESI suggests a challenging market for this niche therapeutic. The initial rapid growth has not been sustained, and recent performance indicates a need for strategic evaluation. The upcoming patent expirations will be a critical juncture, potentially accelerating revenue decline if generic alternatives enter the market.

What Are the Key Competitive Factors for VYLEESI?

The competitive environment for VYLEESI is characterized by a lack of direct pharmacologic competitors, but indirect competition and evolving treatment paradigms are significant.

• Lack of Direct Pharmacologic Competitors: As of 2023, VYLEESI remains the only FDA-approved pharmacologic agent specifically for acquired, generalized HSDD in premenopausal women. This provides a first-mover advantage.
• Indirect Competition from Non-Pharmacologic Therapies:
  • Psychotherapy: Cognitive Behavioral Therapy (CBT) and other forms of sex therapy are widely utilized and recommended for addressing sexual dysfunction, including HSDD. These therapies do not involve drug-related side effects or costs.
  • Lifestyle Modifications: Addressing relationship issues, stress management, and other lifestyle factors can improve sexual desire.
  • Hormone Therapy: While not specifically approved for HSDD, some off-label use of hormone therapy, such as testosterone, may be considered by clinicians in certain contexts, although this is more common in postmenopausal women and carries its own risks.
• Potential Future Competition: The pharmaceutical industry continuously researches new treatments for sexual health conditions. The development of new pharmacologic agents targeting different pathways for HSDD, or improved delivery systems, could emerge in the future.
• Genericization Risk: Upon patent expiration, the market for VYLEESI will likely see the introduction of generic versions of bremelanotide. This would lead to significant price erosion and a substantial decrease in market share for the branded product.
• Physician and Patient Preferences: The decision to prescribe or use VYLEESI is influenced by physician comfort levels with prescribing off-label or novel treatments, patient willingness to use an injectable medication, and their perception of VYLEESI's efficacy relative to its risks and costs.

What is the Future Outlook for VYLEESI?

The future outlook for VYLEESI is complex, balancing its established position in a niche market against patent expirations and evolving treatment landscapes.

• Post-Patent Expiration Impact: The expiration of the primary composition of matter patent in 2027 is the most significant future event. Generic entry will likely lead to a sharp decline in net sales and market share for the branded VYLEESI.
• Life Cycle Management: The manufacturer may explore strategies to extend the product's life cycle, such as seeking approval for new indications, developing improved formulations or delivery devices, or pursuing pediatric exclusivity if applicable. However, given the drug's current sales trajectory and niche indication, significant investment in these areas may be limited.
• Market Penetration Challenges: Continued efforts will be needed to overcome barriers to physician adoption and patient access. This includes ongoing education, patient support programs, and engagement with payers to ensure favorable formulary placement and cost-sharing for patients.
• Emergence of New Therapies: The development of novel, non-pharmacologic or pharmacologic treatments for HSDD could further disrupt the market, even before patent expiration. Continuous monitoring of the R&D pipeline is essential.
• Financial Viability Post-2027: The long-term financial viability of VYLEESI as a branded product will be severely tested post-2027. The manufacturer's strategic decisions regarding continued marketing and support of the branded product will be critical.

Key Takeaways

• VYLEESI's patent protection is primarily based on composition of matter, formulation, and delivery device patents, with the key composition patent expiring in 2027.
• FDA approval in 2019 established VYLEESI as the first pharmacologic treatment for acquired, generalized HSDD in premenopausal women, but post-market surveillance and prescribing information warnings influence its use.
• Market drivers include physician adoption, patient access and affordability, disease awareness, and the drug's specific dosing and administration profile.
• VYLEESI has experienced a decline in net sales in 2022 and 2023 after initial growth, indicating market penetration challenges.
• Competitive factors include the lack of direct pharmacologic competitors but significant indirect competition from non-pharmacologic therapies and the looming threat of genericization post-patent expiration.
• The future outlook is heavily influenced by the 2027 patent expiration, which is expected to lead to substantial revenue decline due to generic competition.

FAQs

1. When does the primary patent for VYLEESI expire, and what is its significance? The primary composition of matter patent for bremelanotide (U.S. Patent No. 7,476,640) is scheduled to expire in 2027. This expiration is significant as it marks the earliest point at which generic versions of bremelanotide can enter the market, likely leading to price erosion and reduced market share for branded VYLEESI.

2. What is the current trend in VYLEESI's net sales? VYLEESI's net sales showed significant growth in its initial years (2020-2021) but have experienced a decline in 2022 (-20.1%) and 2023 (-3.7%). This indicates challenges in sustaining market penetration or increased competitive pressures.

3. Are there any direct pharmacologic competitors to VYLEESI currently on the market? As of the most recent data available, VYLEESI is the only FDA-approved pharmacologic treatment specifically for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

4. What are the main non-pharmacologic approaches that compete with VYLEESI? Non-pharmacologic competitors include psychotherapy, such as Cognitive Behavioral Therapy (CBT) and sex therapy, as well as lifestyle modifications aimed at improving sexual desire.

5. Beyond patent expiration, what other factors could impact VYLEESI's future financial trajectory? Other factors include the successful development and market entry of new pharmacologic or therapeutic agents for HSDD, the effectiveness of ongoing physician education and patient access programs, potential regulatory changes affecting its use or labeling, and the ongoing cost-effectiveness and reimbursement landscape for injectable medications.

Citations

[1] U.S. Patent No. 7,476,640. (2009). [2] U.S. Patent No. 9,867,840. (2018). [3] U.S. Patent No. 10,039,449. (2018). [4] U.S. Food and Drug Administration. (2019, June 21). FDA approves Vyleesi (bremelanotide injection) for acquired generalized hypoactive sexual desire disorder in premenopausal women. [Press Release]. [5] AMAG Pharmaceuticals, Inc. (Various Years). Annual Reports on Form 10-K. U.S. Securities and Exchange Commission. (Specific filings would require access to historical SEC filings). [6] Covis Pharma. (Various Years). Financial Reports and Investor Presentations. (Specific filings would require access to publicly available data from Covis Pharma).